PanoramicaGraficoProfiloStatistiche chiaveDati finanziariNotizie
Derivati
SchermataTrader

CENCORA DL-,01/  US03073E1055  /

Frankfurt
11/11/2024  08:15:45 Var. +2.0500 Volume Denaro13:56:15 Lettera13:56:15 Capitalizzazione di mercato Dividend Y. Rapporto P/E
229.7000EUR +0.90% 0
Fatturato: 0.0000		 231.5000Quantità in denaro: 20 236.2000Quantità in lettera: 20 45.67 bill.EUR - -
GlobeNewswire 28/08 Prevent Cancer Annual Gala to celebrate three decades of commitment to cancer prevention and early d...
GlobeNewswire 14/08 Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
GlobeNewswire 14/08 Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corp...
GlobeNewswire 08/07 Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for...
GlobeNewswire 29/05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 28/05 Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizuma...
GlobeNewswire 15/05 Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Cor...
GlobeNewswire 13/05 Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire 09/05 Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 202...
GlobeNewswire 02/05 Outlook Therapeutics® to Present at the Retina World Congress 2024
GlobeNewswire 29/04 Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Show...
GlobeNewswire 17/04 2024 ICCC Program Provides Free Training, Education, and Mentorship to Small Business Owners
GlobeNewswire 15/04 Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
GlobeNewswire 22/03 Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for ...
GlobeNewswire 18/03 Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
GlobeNewswire 18/03 Parexel Announces CEO Succession Plan
GlobeNewswire 12/03 Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
GlobeNewswire 14/02 Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corp...
GlobeNewswire 23/01 Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-...
GlobeNewswire 02/01 Coherus Announces U.S. Launch of LOQTORZI™
GlobeNewswire 22/12/2023 Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinica...
GlobeNewswire 19/12/2023 Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ...
GlobeNewswire 06/12/2023 Outlook Therapeutics® Announces Strategic Organizational Realignment
GlobeNewswire 27/11/2023 Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path For...
GlobeNewswire 14/11/2023 Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior V...